profit from every $100 of sales.
$0$100
Arcellx
We have no price for Arcellx since 15 May 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$115.07+0.00% today
+30.3% since Oct 8, 25
1-year low $61.831-year high $115.10
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Arcellx sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $22.3 million in 2025, with -$229 million of profit last year.
SalesProfit
Arcellx vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Arcellx | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Arcellx's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 110 | 108 | 22 | |
| – | – | – | – | |
| -191 | -90 | -138 | -253 | |
| -186 | -64 | -99 | -222 | |
| -189 | -71 | -107 | -229 | |
| -5.19 | -1.47 | -2.00 | – | |
| – | – | – | – | |
| – | -81.5% | -127.5% | -1,135.6% | |
| – | -64.1% | -99.5% | -1,027.3% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 314 | 825 | 711 | 604 |
| Cash | 64 | 395 | 106 | 80 |
| Total debt | 88 | 98 | 54 | 52 |
| Total liabilities | 109 | 340 | 257 | 202 |
| 205 | 485 | 455 | 402 | |
| 36 | 48 | 54 | – | |
| -50.4% | -9.0% | -16.2% | -39.8% | |
| -92.1% | -14.6% | -23.6% | -56.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -99 | 208 | -83 | -210 | |
| 2 | 21 | 13 | 2 | |
| -102 | 186 | -97 | -213 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | – | – | |
| 22 | 42 | 61 | 78 |
Valuation
- –
- –
- –
- –
- 302.1×
- –
- –
- -3.2%
- -3.4%
- –
Profitability
- –
- -1,135.6%
- -1,027.3%
- –
- –
- –
- –
- –
- –
- –
Growth
- −55.1%
- –
- –
- –
- –
Financial health
- –
- –
- –
- –
- –
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 889
Bottom 23%of 987
What analysts expect
- Average price target
- $112.45
- Range
- $82.00 – $120.00
- 11 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Feb 26, 2026 | -1.01 | -1.01 | +0.0% |
| Nov 5, 2025 | -0.99 | -0.96 | −3.1% |
| Aug 7, 2025 | -0.94 | -1.03 | +8.7% |
| May 8, 2025 | -1.13 | -0.84 | −34.5% |
| Feb 27, 2025 | -0.87 | -0.63 | −38.1% |
| Nov 7, 2024 | -0.48 | -0.54 | +11.1% |
| Aug 8, 2024 | -0.51 | -0.54 | +5.6% |
| May 9, 2024 | -0.14 | -0.51 | +72.5% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/6Passes 0 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
18No pass
Benjamin Graham
55No pass
Philip Fisher
37No pass
Peter Lynch
–Not enough data
Joel Greenblatt
0No pass
Charlie Munger
27No pass
Terry Smith
32No pass
Questions about Arcellx
Is Arcellx a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Arcellx AI analysis
What does Arcellx do?
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. It is in Biotechnology, based in Redwood City, CA, United States, with 209 employees.
Does Arcellx pay a dividend?
No. Arcellx does not pay a dividend at the moment.
Who are Arcellx's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Arcellx's.
Prices: daily closes to May 15, 2026. Fundamentals: company reports via invest-like data.